Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Q2 revenue increased 10.2% to $3.04 billion, adjusted EPS beat expectations at $3.12, and 2026 revenue guidance was raised. The stock gained 7% over 21 sessions and closed at a period and 52-week high.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Free Cash Flow ⢠Improving Liquidity Position ⢠Elevated Debt Load DGX offers strong cash generation and improving margins/liquidity, but elevated valuation, significant debt, and intangible-heavy assets warrant caution.
Price Behavior
Key Price Behavior Insights: ⢠Sharp rebound ⢠Resistance test ⢠Support nearby Support Level: $237â$240 (stronger: $231â$235) Resistance Level: $247â$248 DGX rebounded sharply over the last month and remains above its ~$241 average, but a decisive break above $247â$248 is needed to sustain momentum while $237â$240 offers initial support.
Sentiment & News
Key News Insights: ⢠Share Price Highs ⢠Alzheimer's Test Expansion ⢠Medicare Cut Risk Quest Diagnostics' strong share momentum and digital/Alzheimer's testing expansion support a defensive growth case, though Medicare reimbursement cuts and debt pressures remain key risks.
AI Summary
Quest's shift toward higher-value diagnostics, consumer access, and operating leverage supports a stronger growth-and-margin profile, but with DGX above analyst targets and near resistance, investors should wait for proof that pricing and utilization gains can withstand 2027 Medicare reimbursement pressure before adding exposure.
Description
Quest Diagnostics is a provider of diagnostic testing and related information services in the U.S. and internationally, offering a spectrum of laboratory testing from routine to advanced clinical and anatomic pathology under multiple brands. Its customers include patients, clinicians, hospitals, health plans, employers and life insurers, and it delivers services through laboratories, patient service centers, physician-office phlebotomists, mobile clinicians and call centers. The company also supplies life-insurance risk assessment services and health care IT solutions and is headquartered in Secaucus, New Jersey, where it was founded in 1967.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Aug 21 | Aug 28 | DGX | Quest Diagnostics Incorporated | Q2 revenue increased 10.2% to $3.04 billion, adjusted EPS beat expectations at $3.12, and 2026 revenue guidance was raised. The stock gained 7% over 21 sessions and closed at a period and 52-week high. | Closed | -0.7% |
| Feb 27 | Mar 6 | DGX | Quest Diagnostics Incorporated | Quest Diagnostics rallied ~28.5% over 21 days on a Q4/FY2025 beat, above-Street FY2026 guidance, a $1B buyback expansion and 7.5% dividend hike; strong FCF and advanced diagnostics launches (Haystack MRD, CoLab expansion) support near-term continuation from pullbacks toward the 190â205 support band. | Closed | -6.0% |